Clinical Trials

15 enrolled

Leukemia, Myeloid, Chronic-Phase

NCT05559008 2022-11-09

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Phase 1/2 Unknown

116 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT03173612 2022-08-03

The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

132 enrolled

Leukemia, Myeloid, Acute

NCT04155411 2022-07-27

Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP

Phase 4 Unknown

65 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03564470 2022-07-01

Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL

Phase 2/3 Unknown

120 enrolled

Leukemia, Leukemia, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05042531 2022-04-25

Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia

30 enrolled

Leukemia, Myeloid, Acute

NCT05024357 2021-10-01

A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL

80 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05026229 2021-10-01

A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL

60 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04578847 2020-10-08

READIT

100 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02638428 2020-03-19

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

90 enrolled

Other solid neoplasm

Relapsed Pediatric Solid Tumor

NCT04284202 2020-02-25

PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02268370 2019-11-29

TRAD

131 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02233049 2018-07-23

BIOMEDE

250 enrolled

CNS

Diffuse Intrinsic Pontine Glioma

NCT02744768 2018-03-22

D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia

60 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03216070 2017-07-13

Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia

Phase 4 Unknown

12 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01685125 2017-07-07

Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

96 enrolled

Genitourinary

Prostatic Neoplasms

NCT02015728 2016-12-15

SEED

20 enrolled

Neoplasms, Recurrence

NCT02776878 2016-05-18

A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST

57 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01802450 2015-09-17

DASAPOST

18 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01887561 2013-06-27

Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial

100 enrolled

Leukemia, Myeloid, Chronic-Phase

NCT01627132 2012-06-25

Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial

50 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01051115 2011-08-31

D'ACCORD

35 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00112775 2011-06-07

BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00979160 2009-09-18

Evaluation of Response of Dasatinib to Treat Mastocytosis